Source
Department of Obstetrics and Gynecology, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, CancerEst, Université Pierre et Marie Curie (UPMC), Paris, France.
Abstract
OBJECTIVE:
To evaluate the feasibility and effectiveness of using TachoSil during obstetric and gynecologic surgery.
METHODS:
The retrospective cohort study, conducted at a French university hospital, included women who experienced perioperative bleeding requiring the use of TachoSil during 2007-2009. The following information was collected: patient age, indication for the use of TachoSil, need for a blood transfusion, type of surgery performed, postoperative course, and traceability of TachoSil.
RESULTS:
TachoSil was used in 84 women. The main indications for the surgical interventions requiring TachoSil were ovarian malignancy (n=18), fibroma (n=17), breast cancer (n=11), and endometrial cancer (n=10). In 16 women, TachoSil was applied to the uterine serosa, particularly after cesarean delivery or polymyomectomy; in 7 women, it was applied to the major vascular axis. Red cell packs were infused in 24 women during surgery (average 3 packs per woman). Three women required repeat surgery. The use of TachoSil was not recorded in the operative reports of 43 (51%) women.
CONCLUSION:
The present findings confirm that the use of TachoSil in gynecologic and obstetric surgeries is effective and well tolerated. Measures to improve the traceability of TachoSil use are recommended.
Copyright © 2011 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. All rights reserved.